page 1 of 14 pid d040002 date april 19 2005 from lt kendra worthy pharm d usphs drug use specialist division surveillance research and communication support hfd 410 through gerald dalpan md mhs director to solomon iyasu mph pediatric development 960 office counter terrorism subject one year post exclusivity marketing adverse event review data tolterodine detrol tablets nda 20 771 la 21 241 this document contains proprietary ims health caremark which cannot be shared outside fda without clearance obtained the safety executive summary consult examines utilization trends for products in population ages 16 years with a primary focus on patterns before following granting january 5 2004 databases licensed by agency were used determine various retail non channels distribution although majority product usage occurs outpatient setting we
